Patents by Inventor Edward L. Halk

Edward L. Halk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to alpha-synuclein and uses thereof
    Patent number: 11827695
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: November 28, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
  • Antibodies to alpha-synuclein and uses thereof
    Patent number: 11142570
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: October 12, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20210221878
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Application
    Filed: January 19, 2021
    Publication date: July 22, 2021
    Inventors: Michael K. AHLIJANIAN, Jere Ernest MEREDITH, Jr., Nino DEVIDZE, John David GRAEF, Edward L. HALK
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20200231661
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Application
    Filed: February 16, 2018
    Publication date: July 23, 2020
    Inventors: Michael K. AHLIJANIAN, Jere Ernest MEREDITH, Jr., Nino DEVIDZE, John David GRAEF, Edward L. HALK
  • HUMAN CTLA-4 ANTIBODIES AND THEIR USES
    Publication number: 20190119384
    Abstract: The presently subject matter provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: December 26, 2018
    Publication date: April 25, 2019
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • FULLY HUMAN ANTIBODIES TO BTLA
    Publication number: 20190119381
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: October 31, 2018
    Publication date: April 25, 2019
    Inventors: Jennifer Marie MATARAZA, Andrea Van ELSAS, Alan J. KORMAN, Edward L. HALK, Kent B. THUDIUM, Mark J. SELBY, Timothy W. SPROUL, Heidi N. LEBLANC
  • FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
    Publication number: 20190062445
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: September 20, 2018
    Publication date: February 28, 2019
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Fully human antibodies to BTLA
    Patent number: 10155813
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 18, 2018
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark J. Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Transgenic transchromosomal rodents for making human antibodies
    Patent number: 10076103
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 18, 2018
    Assignees: KYOWA HAKKO KIRIN CO., LTD., E.R. SQUIBB & SONS, L.L.C.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
    Publication number: 20160368998
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: June 6, 2016
    Publication date: December 22, 2016
    Inventors: Maria JURE-KUNKEL, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • TRANSGENIC TRANSCHROMOSOMAL RODENTS FOR MAKING HUMAN ANTIBODIES
    Publication number: 20160324131
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 10, 2016
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • HUMAN CTLA-4 ANTIBODIES AND THEIR USES
    Publication number: 20160257753
    Abstract: The presently subject matter provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 8, 2016
    Applicant: E.R. Squibb & Sons, L.L.C.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Transgenic transchromosomal rodents for making human antibodies
    Patent number: 9426970
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: August 30, 2016
    Assignees: E. R. SQUIBB & SONS, L.L.C., KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • FULLY HUMAN ANTIBODIES TO BTLA
    Publication number: 20160222114
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 4, 2016
    Inventors: Jennifer Marie MATARAZA, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark J. Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Fully human antibodies against human 4-1BB
    Patent number: 9382328
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 5, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Fully human antibodies to BTLA
    Patent number: 9346882
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: May 24, 2016
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark J. Selby, Timothy W. Sproul, Heidi N. Leblanc
  • TRANSGENIC TRANSCHROMOSOMAL RODENTS FOR MAKING HUMAN ANTIBODIES
    Publication number: 20140380515
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 25, 2014
    Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
  • Transgenic trasnchromosomal rodents for making human antibodies
    Patent number: 8835712
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: September 16, 2014
    Assignees: Medarex, L.L.C., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • HUMAN CTLA-4 ANTIBODIES AND THEIR USES
    Publication number: 20140234331
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: Medarex, L.L.C.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Human CTLA-4 antibodies and their uses
    Patent number: 8784815
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: July 22, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler